JPH0344324A - Sexual function invigorator - Google Patents

Sexual function invigorator

Info

Publication number
JPH0344324A
JPH0344324A JP18086789A JP18086789A JPH0344324A JP H0344324 A JPH0344324 A JP H0344324A JP 18086789 A JP18086789 A JP 18086789A JP 18086789 A JP18086789 A JP 18086789A JP H0344324 A JPH0344324 A JP H0344324A
Authority
JP
Japan
Prior art keywords
propentofylline
sexual function
invigorator
agent
antasthenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP18086789A
Inventor
Kazuoki Tsuchiya
Original Assignee
Kazuoki Tsuchiya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kazuoki Tsuchiya filed Critical Kazuoki Tsuchiya
Priority to JP18086789A priority Critical patent/JPH0344324A/en
Publication of JPH0344324A publication Critical patent/JPH0344324A/en
Application status is Pending legal-status Critical

Links

Abstract

PURPOSE: To obtain sexual function invigorator having excellent action stimulating hypothalamus or limbic system and invigorating sexual function containing propentofylline or intracorporeal metabolite of said propentofylline as active ingredient.
CONSTITUTION: The aimed sexual function invigorator contains propentofylline [namely, xantine derivative such as 3-methyl-1-(5-oxohexyl)-7-propyl-7H-purine-2(3 H),6(1H)-dione] or intracorporeal metabolite of said compound (namely, 5- oxohexyl in the propentofylline is modified to 5-hydroxyhexyl, 4-carboxybutyl or 3-carboxypropyl) as active ingredient. Said agent is useful as a tonic or an antasthenic agent. Said agent is also useful by subjecting to oral administration as a drug or adding to various foods as a nourishing antasthenic food.
COPYRIGHT: (C)1991,JPO&Japio
JP18086789A 1989-07-13 1989-07-13 Sexual function invigorator Pending JPH0344324A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP18086789A JPH0344324A (en) 1989-07-13 1989-07-13 Sexual function invigorator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18086789A JPH0344324A (en) 1989-07-13 1989-07-13 Sexual function invigorator

Publications (1)

Publication Number Publication Date
JPH0344324A true JPH0344324A (en) 1991-02-26

Family

ID=16090740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18086789A Pending JPH0344324A (en) 1989-07-13 1989-07-13 Sexual function invigorator

Country Status (1)

Country Link
JP (1) JPH0344324A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05216816A (en) * 1992-02-06 1993-08-27 Pfu Ltd Bus control circuit
US5981527A (en) * 1995-07-14 1999-11-09 Icos Corporation Cyclic GMP-specific phosphodiesterase inhibitors
US6001847A (en) * 1995-07-14 1999-12-14 Icos Corporation Chemical compounds
WO2000007541A3 (en) * 1998-07-31 2000-05-04 Aventis Pharma Gmbh Use of xanthine derivatives for treating erectile disorder
US6117881A (en) * 1996-05-10 2000-09-12 Icos Corporation N-cinnamoyl derivatives of (β) carbolines
US6140329A (en) * 1995-07-14 2000-10-31 Icos Corporation Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6300335B1 (en) 1994-11-26 2001-10-09 Pfizer Inc. 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
EP1214938A2 (en) * 1991-05-24 2002-06-19 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
US6469012B1 (en) 1993-06-09 2002-10-22 Pfizer Inc Pyrazolopyrimidinones for the treatment of impotence
US6534511B1 (en) 1994-11-26 2003-03-18 Pfizer Inc. Bicyclic heterocyclic compounds for the treatment of impotence
JP2015183003A (en) * 2014-03-25 2015-10-22 クワン ドン ファーマシューティカル カンパニー,リミテッド Male sterility preventive and therapeutic pharmaceutical composition containing mixtures of rehmannia glutinosa liboschitz var.purpurae makino, lycium chinense miller, aquillaria agallocha roxburgh, poria cocos wolf, panax ginseng ca meyer and honey as active ingredients

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214938A3 (en) * 1991-05-24 2003-08-06 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
EP1214938A2 (en) * 1991-05-24 2002-06-19 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
JPH05216816A (en) * 1992-02-06 1993-08-27 Pfu Ltd Bus control circuit
US6469012B1 (en) 1993-06-09 2002-10-22 Pfizer Inc Pyrazolopyrimidinones for the treatment of impotence
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6656945B2 (en) 1994-11-26 2003-12-02 Pfizer Inc 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction
US6534511B1 (en) 1994-11-26 2003-03-18 Pfizer Inc. Bicyclic heterocyclic compounds for the treatment of impotence
US6300335B1 (en) 1994-11-26 2001-10-09 Pfizer Inc. 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
US6218400B1 (en) 1995-07-14 2001-04-17 Icos Corporation Treatment method using a cGMP-Specific PDE inhibitor
US5981527A (en) * 1995-07-14 1999-11-09 Icos Corporation Cyclic GMP-specific phosphodiesterase inhibitors
US6140329A (en) * 1995-07-14 2000-10-31 Icos Corporation Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence
US6001847A (en) * 1995-07-14 1999-12-14 Icos Corporation Chemical compounds
US6608065B1 (en) 1995-07-14 2003-08-19 Icos Corporation Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction
US6117881A (en) * 1996-05-10 2000-09-12 Icos Corporation N-cinnamoyl derivatives of (β) carbolines
US6306870B1 (en) 1996-05-10 2001-10-23 Icos Corporation N-cinnamoyl derivatives of beta-carboline
WO2000007541A3 (en) * 1998-07-31 2000-05-04 Aventis Pharma Gmbh Use of xanthine derivatives for treating erectile disorder
JP2015183003A (en) * 2014-03-25 2015-10-22 クワン ドン ファーマシューティカル カンパニー,リミテッド Male sterility preventive and therapeutic pharmaceutical composition containing mixtures of rehmannia glutinosa liboschitz var.purpurae makino, lycium chinense miller, aquillaria agallocha roxburgh, poria cocos wolf, panax ginseng ca meyer and honey as active ingredients

Similar Documents

Publication Publication Date Title
AU623599B2 (en) Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic amp
KR910002379A (en) The composition and method for improving the physiological response to exercise
ZA8502168B (en) Galenic form for oral administration and its method of preparation by lyophilization of an oil-in-water emulsion
ES2187578T3 (en) bicyclic heterocyclic compounds for the treatment of impotence.
CA2014889A1 (en) Intra-rectal pharmaceutical foam compositions
HUT44081A (en) Process for producing avermectin derivatives and pharmaceutical compositions containing them as active components
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CA2046679A1 (en) Pharmaceutical composition for rapid suspension in water
HUT46000A (en) Process for producing imidazo/4,5-b/pyridine derivatives and pharmaceutics comprising these compounds as active ingredient
JPH02215707A (en) Skin cosmetic
IL85316D0 (en) Nona-and decapeptide analogs of lhrh,their preparation and pharmaceutical compositions containing them
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
HUT46654A (en) Process for producing substituted basic 2-amino-tetralin derivatives and pharmaceutical compositions comprising the same as active ingredient
HU9008407D0 (en) Process for the production of purine nucleoside derivatives and medical preparations containing them as active agents
EP0269574A3 (en) Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
SE503312C2 (en) A pharmaceutical preparation containing a granulocyte colony stimulating factor G-CSF
IL96875A (en) Ureido derivatives of poly-4-amino-2-carboxy-1-methyl-pyrroles, certain such pharmaceutically active compounds, their preparation and pharmaceutical compositions containing them
HUT58511A (en) Process for producing pharmaceutical compositions comprising toremifen and its metabolites, suitable for ceasing the simultaneous resistance of cancer cells to several cytotoxic active ingredients
TW420615B (en) Aqueous risperidone formulations
HUT59151A (en) Process for producing purinylphosphonic acid derivatives and pharmaceutical compositions comprising same as active ingredient
FI943315A0 (en) The pharmaceutical preparation of effervescent and / or in the form hajoamistabletin or pikarakeiden, as well as the method to prepare them
HUT61732A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising same as active ingredient
EP0495349A3 (en) Composition of an active agent for oral administration, especially to ruminants
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
HUT53888A (en) Fungicides comprising pyrimidine derivatives as active ingredient and process for producing the active ingredients